Kyntra Bio, Inc. (KYNB)

Kyntra Bio, Inc. (KYNB) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $23.8M; returns 1 day -12.3%, 1 week -5.6%.

Kyntra Bio, Inc. (KYNB), formerly FibroGen, is a biopharmaceutical company focused on the development and commercialization of therapeutics for unmet medical needs in prostate cancer and anemia. Kyntra Bio rebrands to reflect a new era of focus and momentum. Kyntra Bio's revenue for the latest twelve months ending September 30, 2025, was $8.298 million.

Groups KYNB belongs to

• Biotechnology
• Biopharmaceutical
• Healthcare
• Oncology
• Life Sciences
• Clinical Stage Biopharma
• Commercial Stage Biotech
• Pharmaceuticals
• Unmet Medical Needs

KYNB financial model: income statement, cash flow and balance sheet